Cowey CL - Search Results

1

HIF1α and HIF2α exert distinct nutrient preferences in renal cells.

Arreola A, Cowey CL, Coloff JL, Rathmell JC, Rathmell WK. Arreola A, et al. Among authors: cowey cl. PLoS One. 2014 May 30;9(5):e98705. doi: 10.1371/journal.pone.0098705. eCollection 2014. PLoS One. 2014. PMID: 24879016 Free PMC article.

2

VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy.

Cowey CL, Rathmell WK. Cowey CL, et al. Curr Oncol Rep. 2009 Mar;11(2):94-101. doi: 10.1007/s11912-009-0015-5. Curr Oncol Rep. 2009. PMID: 19216840 Free PMC article. Review.

3

VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo.

Lee CM, Hickey MM, Sanford CA, McGuire CG, Cowey CL, Simon MC, Rathmell WK. Lee CM, et al. Among authors: cowey cl. Oncogene. 2009 Apr 9;28(14):1694-705. doi: 10.1038/onc.2009.12. Epub 2009 Mar 2. Oncogene. 2009. PMID: 19252526 Free PMC article.

4

The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response.

Cowey CL, Fielding JR, Rathmell WK. Cowey CL, et al. Urology. 2010 May;75(5):1108-13.e1. doi: 10.1016/j.urology.2009.06.105. Epub 2009 Nov 20. Urology. 2010. PMID: 19931124

5

Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.

Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G, Watkins C, Nance KV, Crane J, Jalkut M, Moore DT, Kim WY, Godley PA, Whang YE, Fielding JR, Rathmell WK. Cowey CL, et al. J Clin Oncol. 2010 Mar 20;28(9):1502-7. doi: 10.1200/JCO.2009.24.7759. Epub 2010 Feb 16. J Clin Oncol. 2010. PMID: 20159822 Free PMC article. Clinical Trial.

6

Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma.

Cowey CL, Rathmell WK. Cowey CL, et al. Expert Opin Drug Discov. 2008 Mar;3(3):311-327. doi: 10.1517/17460441.3.3.311. Expert Opin Drug Discov. 2008. PMID: 20648240 Free PMC article.

7

Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib.

Khandani AH, Cowey CL, Moore DT, Gohil H, Rathmell WK. Khandani AH, et al. Among authors: cowey cl. Nucl Med Commun. 2012 Sep;33(9):967-73. doi: 10.1097/MNM.0b013e3283561837. Nucl Med Commun. 2012. PMID: 22714005 Clinical Trial.

8

FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.

Chen JL, Appelbaum DE, Kocherginsky M, Cowey CL, Rathmell WK, McDermott DF, Stadler WM. Chen JL, et al. Among authors: cowey cl. Cancer Med. 2013 Aug;2(4):545-52. doi: 10.1002/cam4.102. Epub 2013 Jul 10. Cancer Med. 2013. PMID: 24156027 Free PMC article. Clinical Trial.

9

New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib.

Cowey CL, Sonpavde G, Hutson TE. Cowey CL, et al. Onco Targets Ther. 2010 Oct 5;3:147-55. doi: 10.2147/ott.s12480. Onco Targets Ther. 2010. PMID: 21049083 Free PMC article.

10

Sequential use of targeted agents in the treatment of renal cell carcinoma.

Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B, Sternberg CN. Hutson TE, et al. Among authors: cowey cl. Crit Rev Oncol Hematol. 2011 Jan;77(1):48-62. doi: 10.1016/j.critrevonc.2010.07.018. Epub 2010 Aug 11. Crit Rev Oncol Hematol. 2011. PMID: 20705477 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

53 results

Search Page

Filters